Narcolepsy News and Research

RSS

Narcolepsy is a chronic sleep disorder, or dyssomnia. The condition is characterized by excessive daytime sleepiness (EDS) in which a person experiences extreme fatigue and possibly falls asleep at inappropriate times, such as while at work or at school.

Sleep paralysis can be strange and frightening experience but not harmful

Your eyes begin to open after a good night of sleep, but something feels weird. You try to rub the tiredness out of your face but can't lift your arms. In a panic you try to take a deep breath but can't draw air.

20 Sep 2016

FDA takes action against websites that illegally sell unapproved prescription drugs

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 websites that illegally sell potentially dangerous, unapproved prescription drugs to U.S. consumers.

10 Jun 2016

Misuse of Adderall drug rising among young adults, research suggests

While the number of prescriptions for the stimulant Adderall has remained unchanged among young adults, misuse and emergency room visits related to the drug have risen dramatically in this group, new Johns Hopkins Bloomberg School of Public Health research suggests.

17 Feb 2016

Genetic variants associated with preference to mornings or nights

23andMe, Inc., the leading personal genetics company, today announced the results of a genome-wide association study (GWAS) identifying genetic variants associated with being a morning person.

3 Feb 2016

CPMC study discovers six genes that affect sleep duration

The Coriell Personalized Medicine Collaborative, a research initiative exploring the utility of genetic information in the clinical setting, has published a study and identified six noteworthy genes that affect human sleep duration.

13 Jan 2016

Study on how immune systems of astronauts respond to seasonal flu vaccine

Every year, as influenza season - and flu shot season--rolls around, medical experts weigh in on just how effective it will be against that year's particular strain. What if that equation could take into account a person's own immune response?

24 Dec 2015

Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

Hiroshi Nagase, a Professor at the International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, collaborated with Masashi Yanagisawa (Professor / Director of WPI-IIIS) and successfully developed a potent compound that promotes wakefulness and remedies the sleep disorder narcolepsy in model animals.

18 Nov 2015

Study: Children with TBI more likely to experience daytime sleepiness, sleep disturbances

A new study suggests that children with traumatic brain injuries (TBI) have poorer sleep and more daytime sleepiness in comparison to healthy children.

9 Jun 2015

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

8 Jun 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

AASM publishes new quality measures for common sleep disorders

Today the American Academy of Sleep Medicine published new quality measures for five common sleep disorders, which represents a landmark achievement in the promotion of high quality, patient-centered care in the medical subspecialty of sleep medicine.

16 Mar 2015

Narcolepsy bears trademarks of classic autoimmune disorder

Narcoleptics suffer from bouts of sleepiness and sleep attacks, which impair their ability to function in daily life. But the precise cause of narcolepsy has long eluded scientists, and the cure for the devastating neurological disorder afflicting an estimated three million people worldwide -- and one in 3,000 Americans -- remains at bay.

10 Mar 2015

Adolescents experience excessive daytime sleepiness due to marijuana use

A study published recently by researchers from Nationwide Children's Hospital, found 10 percent of adolescents sent to a Sleep Center for evaluation of excessive daytime sleepiness with testing results consistent with narcolepsy had urine drug screens positive for marijuana, confounding the results.

16 Feb 2015

Merck announces US availability of BELSOMRA (suvorexant) for treatment of insomnia

Merck, known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep.

4 Feb 2015

Protein that awakens brain from sleep may fight against Alzheimer's disease

A protein that stimulates the brain to awaken from sleep may be a target for preventing Alzheimer's disease, a study by researchers at Washington University School of Medicine in St. Louis suggests.

25 Nov 2014

MGH investigators develop system to accurately track the process of falling asleep

Massachusetts General Hospital investigators have developed a system to accurately track the dynamic process of falling asleep, something has not been possible with existing techniques. In their report in the October issue of the open-access journal PLOS Computational Biology, the research team describes how combining key physiologic measurements with a behavioral task that does not interfere with sleep onset gives a better picture of the gradual process of falling asleep.

21 Nov 2014

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors.

15 Aug 2014

Narcolepsy News and Research

Further Reading

Sleep paralysis can be strange and frightening experience but not harmful

FDA takes action against websites that illegally sell unapproved prescription drugs

Misuse of Adderall drug rising among young adults, research suggests

Genetic variants associated with preference to mornings or nights

CPMC study discovers six genes that affect sleep duration

Study on how immune systems of astronauts respond to seasonal flu vaccine

Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

Study: Children with TBI more likely to experience daytime sleepiness, sleep disturbances

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

AASM publishes new quality measures for common sleep disorders

Narcolepsy bears trademarks of classic autoimmune disorder

Adolescents experience excessive daytime sleepiness due to marijuana use

Merck announces US availability of BELSOMRA (suvorexant) for treatment of insomnia

Protein that awakens brain from sleep may fight against Alzheimer's disease

MGH investigators develop system to accurately track the process of falling asleep

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Proteins causing daytime sleepiness also play crucial role in bone formation

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Snapping at new biotech breakthroughs with Gator Pro

Realizing the Importance of Medical Electronic Devices

Everything about SpatialOMx

Latest News

Lab Diagnostics and Automation eBook